Cascadian Therapeutics, Inc. (CASC) Earns Underweight Rating from Analysts at Barclays PLC
Barclays PLC initiated coverage on shares of Cascadian Therapeutics, Inc. (NASDAQ:CASC) in a research note released on Wednesday, Marketbeat reports. The firm issued an underweight rating and a $4.00 price objective on the biopharmaceutical company’s stock.
Several other research analysts have also recently commented on CASC. Cowen and Company restated a buy rating on shares of Cascadian Therapeutics in a report on Tuesday, May 9th. Cantor Fitzgerald restated a hold rating and set a $4.00 target price on shares of Cascadian Therapeutics in a report on Wednesday, May 10th. Zacks Investment Research cut shares of Cascadian Therapeutics from a buy rating to a hold rating in a report on Friday, May 19th. Finally, ValuEngine cut shares of Cascadian Therapeutics from a sell rating to a strong sell rating in a report on Friday, June 2nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of $5.63.
Cascadian Therapeutics (NASDAQ:CASC) opened at 3.59 on Wednesday. The stock’s 50 day moving average is $3.77 and its 200-day moving average is $3.94. Cascadian Therapeutics has a 12-month low of $0.84 and a 12-month high of $6.72. The company’s market cap is $181.49 million.
Cascadian Therapeutics (NASDAQ:CASC) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.06. During the same quarter last year, the firm posted ($1.57) earnings per share. Analysts predict that Cascadian Therapeutics will post $5.02 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Cascadian Therapeutics, Inc. (CASC) Earns Underweight Rating from Analysts at Barclays PLC” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/10/cascadian-therapeutics-inc-casc-earns-underweight-rating-from-analysts-at-barclays-plc.html.
A number of institutional investors and hedge funds have recently made changes to their positions in CASC. Acadian Asset Management LLC acquired a new position in Cascadian Therapeutics during the first quarter worth $238,000. TFS Capital LLC acquired a new position in Cascadian Therapeutics during the first quarter worth $314,000. Oxford Asset Management boosted its holdings in Cascadian Therapeutics by 32.9% during the first quarter. Oxford Asset Management now owns 162,192 shares of the biopharmaceutical company’s stock worth $671,000 after purchasing an additional 40,117 shares during the last quarter. NEA Management Company LLC boosted its holdings in Cascadian Therapeutics by 405.9% during the first quarter. NEA Management Company LLC now owns 9,064,575 shares of the biopharmaceutical company’s stock worth $37,527,000 after purchasing an additional 7,272,909 shares during the last quarter. Finally, Sphera Funds Management LTD. acquired a new position in Cascadian Therapeutics during the first quarter worth $2,406,000. Institutional investors and hedge funds own 82.55% of the company’s stock.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Stock Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related stocks with our FREE daily email newsletter.